Validation of the M. D. Anderson Symptom Inventory multiple myeloma module

Journal of Hematology & Oncology

Tito R Mendoza²  Charles S Cleeland²  Richard E Champlin³  Valen E Johnson¹  Sheeba K Thomas⁴  Nina D Shah³  Loretta A Williams²  Xin Shelley Wang²  Elisabeth G Vichaya²  Desiree Jones² 

[1] Current address: Department of Statistics, Texas A&M University, 525K Blocker, 3143 TAMU, College Station, 77843-3143, Houston, TX, USA;Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, 77030, Houston, TX, USA;Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, 77030, Houston, TX, USA;Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, 77030, Houston, TX, USA

关键词: MDASI;    Multiple myeloma;    Validation;    Assessment;    Symptoms;   

Others  :  812628
DOI  :  10.1186/1756-8722-6-13

 received in 2012-11-27, accepted in 2013-01-31,  发布年份 2013

【 摘 要 】

Background

The symptom burden associated with multiple myeloma (MM) is often severe. Presently, no instrument comprehensively assesses disease-related and treatment-related symptoms in patients with MM. We sought to validate a module of the M. D. Anderson Symptom Inventory (MDASI) developed specifically for patients with MM (MDASI-MM).

Methods

The MDASI-MM was developed with clinician input, cognitive debriefing, and literature review, and administered to 132 patients undergoing induction chemotherapy or stem cell transplantation. We demonstrated the MDASI-MM’s reliability (Cronbach α values); criterion validity (item and subscale correlations between the MDASI-MM and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EORTC MM module (QLQ-MY20)), and construct validity (differences between groups by performance status). Ratings from transplant patients were examined to demonstrate the MDASI-MM’s sensitivity in detecting the acute worsening of symptoms post-transplantation.

Results

The MDASI-MM demonstrated excellent correlations with subscales of the 2 EORTC instruments, strong ability to distinguish clinically different patient groups, high sensitivity in detecting change in patients’ performance status, and high reliability. Cognitive debriefing confirmed that the MDASI-MM encompasses the breadth of symptoms relevant to patients with MM.

Conclusion

The MDASI-MM is a valid, reliable, comprehensive-yet-concise tool that is recommended as a uniform symptom assessment instrument for patients with MM.

【 授权许可】

   
2013 Jones et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Brenner H, Gondos A, Pulte D: Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008, 111:2521-2526.
• [2]Catley L, Anderson K: Strategies to improve the outcome of stem cell transplantation in multiple myeloma. The hematology journal: the official journal of the European Haematology Association/EHA 2004, 5:9-23.
• [3]Chapko MK, Syrjala KL, Schilter L, Cummings C, Sullivan KM: Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea. Bone Marrow Transplant 1989, 4:181-186.
• [4]Leger CS, Bredeson C, Kearns B, Bence-Bruckler I, Atkins H, Huebsch L: Autologous blood and marrow transplantation in patients 60 years and older. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 2000, 6:204-210.
• [5]Sherman AC, Simonton S, Latif U, Spohn R, Tricot G: Psychosocial adjustment and quality of life among multiple myeloma patients undergoing evaluation for autologous stem cell transplantation. Bone Marrow Transplant 2004, 33:955-962.
• [6]Wisloff F, Eika S, Hippe E, Hjorth M, Holmberg E, Kaasa S, Palva I, Westin J: Measurement of health-related quality of life in multiple myeloma. Nordic myeloma study group. British journal of haematology 1996, 92:604-613.
• [7]Cocks K, Cohen D, Wisloff F, Sezer O, Lee S, Hippe E, Gimsing P, Turesson I, Hajek R, Smith A: An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. European journal of cancer (Oxford, England: 1990) 2007, 43:1670-1678.
• [8]Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC: Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000, 89:1634-1646.
• [9]Dubois D, Dhawan R, van de Velde H, Esseltine D, Gupta S, Viala M, de la Loge C: Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2006, 24:976-982.
• [10]Wagner LI, Robinson D Jr, Weiss M, Katz M, Greipp P, Fonseca R, Cella D: Content development for the functional assessment of cancer therapy-multiple myeloma: Use of qualitative and quantitative methods for scale construction. J Pain Symptom Manage 2012, 43:1094-1104.
• [11]Kirkova J, Davis MP, Walsh D, Tiernan E, O’Leary N, LeGrand SB, Lagman RL, Russell KM: Cancer symptom assessment instruments: a systematic review. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2006, 24:1459-1473.
• [12]Gning I, Trask PC, Mendoza TR, Harle MT, Gutierrez KA, Kitaka SA, Sherman SI, Cleeland CS: Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory. Oncology 2009, 76:59-68.
• [13]Armstrong TS, Mendoza T, Gning I, Coco C, Cohen MZ, Eriksen L, Hsu MA, Gilbert MR, Cleeland C: Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). Journal of neuro-oncology 2006, 80:27-35.
• [14]Mendoza TR, Wang XS, Lu C, Palos GR, Liao Z, Mobley GM, Kapoor S, Cleeland CS: Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. The oncologist 2011, 16:217-227.
• [15]Rosenthal DI, Mendoza TR, Chambers MS, Asper JA, Gning I, Kies MS, Weber RS, Lewin JS, Garden AS, Ang KK: Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck 2007, 29:923-931.
• [16]Willis GRB, Barofsky I: The use of cognitive interviewing techniques in quality of life and patient-reported outcomes assessment. In Outcomes Assessment in Cancer: Measures, Methods, and Applications. Edited by Lipscomb J, Gotay CC, Snyder C. Cambridge: Cambridge University Press; 2005:610-622.
• [17]Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS: When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995, 61:277-284.
• [18]Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL: The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999, 85:1186-1196.
• [19]Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
• [20]Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
• [21]Cleeland CS, Gonin R, Baez L, Loehrer P, Pandya KJ: Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. Annals of internal medicine 1997, 127:813-816.
• [22]Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ: Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994, 330:592-596.
• [23]Nunnally J, Bernstein IH: Pscyhometric Theory. 3rd edition. New York: McGraw-Hill; 1994.
• [24]Sloan JA, Vargas-Chanes D, Kamath CC, Sargent DJ, Novotny PJ, Atherton P: Detecting worms, ducks and elephants: A simple approach for defining clinically relevant effects in qualty-of-life measures. J Cancer Integr Med 2003, 1(1):41-47.
• [25]Cohen J: Statistical Power Analysis for the Behavioral Sciences. 2nd edition. NJ: Lawrence Earlbaum Associates; 1988.
• [26]Cohen J: A power primer. Psychol Bull 1992, 112:155-159.
• [27]Efficace F, Novik A, Vignetti M, Mandelli F, Cleeland CS: Health-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: where are we now and where do we go from here? Haematologica 2007, 92:1596-1598.
• [28]Fairclough DL: Patient reported outcomes as endpoints in medical research. Stat Methods Med Res 2004, 13:115-138.
• [29]Mystakidou K, Cleeland C, Tsilika E, Katsouda E, Primikiri A, Parpa E, Vlahos L, Mendoza T: Greek M.D. Anderson Symptom Inventory: validation and utility in cancer patients. Oncology 2004, 67:203-210.
• [30]Nejmi M, Wang XS, Mendoza TR, Gning I, Cleeland CS: Validation and application of the Arabic version of the M. D. Anderson symptom inventory in Moroccan patients with cancer. Journal of pain and symptom management 2010, 40:75-86.
• [31]Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS, Uchitomi Y: Japanese version of the MD Anderson Symptom Inventory: a validation study. J Pain Symptom Manage 2003, 26:1093-1104.
• [32]Wang XS, Wang Y, Guo H, Mendoza TR, Hao XS, Cleeland CS: Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients. Cancer 2004, 101:1890-1901.
• [33]Yun YH, Mendoza TR, Kang IO, You CH, Roh JW, Lee CG, Lee WS, Lee KS, Bang SM, Park SM: Validation study of the Korean version of the M. D. Anderson Symptom Inventory. Journal of pain and symptom management 2006, 31:345-352.